Notably, while some clinical AD cases exhibit Aβ-PET negativity, and certain FTD patients may display temporal atrophy due to comorbid tau pathology, genetic testing remains critical for definitive diagnosis. This evidence concerns the gene MAPT and frontotemporal dementia.